Proteocyte Announces Mark Hammar as new CEO

Toronto, ON; January 19, 2022 – Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient’s risk of developing oral cancer, is pleased to announce the appointment of Mark Hammar as Chief Executive Officer,...

Proteocyte Selects Medlior as Health Outcomes Research Provider

MaRS Discovery District, Toronto, ON; December 1, 2021 – Proteocyte AI is pleased to announce its formal engagement with Medlior, a health outcomes research provider based in Calgary, Alberta. Proteocyte will rely on Medlior’s team of diverse subject...

Proteocyte Completes Successful Financing Round of $1.1 Million

MaRS Discovery District, Toronto, ON; August 4, 2021 – Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient’s risk of developing oral cancer, is pleased to announce it has recently completed its latest...

First International Clinical Advisory Board Meeting

MaRS Discovery District, Toronto, ON; January 18, 2021 – Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Center, Toronto ON, announces today that the first Clinical Advisory Board (CAB) meeting with some of the most renowned global...